Substitute for form 1449A/B/PTO.

INFORMATION DISCLOSTED STATEMENT BY APPLICANT

Sheet 1 of 12

NUV 2 2 2004 **U.S. PATENT DOCUMENTS** U.S. Patent Document Examiner Application or Kind Date of Filing Date If Name of Patentee or Applicant Initials Patent Number Code Publication · Appropriate 2803582 NIC Chemey 8/20/1957 3137631 2 Soloway 6/16/1964 3 3216897 Krantz et al. 11/9/1965 3274063 4 Nieper et al. 9/20/1966 3440318 5 Polin 4/22/1969 3594476 6 Merrill 7/20/1971 3715432 Merrill 2/6/1973 8 3755557 Jacobs 8/28/1973 9 3776857 Lindner 12/4/1973 10 3794476 Michalik et al. 2/26/1974 11 3937668 Zolle 2/10/1976 12 3960757 Morishita et al. 6/1/1976 3965255 Bloch et al. 6/22/1976 13 Suzuki et al. 14 4016100 4/5/1977 15 4053585 Allison et al. 10/11/1977 4073943 2/14/1978 16 Wretlind et al. **Papahadjopoulos** 3/7/1978 17 4078052 Schneider 5/16/1978 18 4089801 4102806 Kondo et al. 7/25/1978 19 8/15/1978 20 Oppenheim et al. 4107288 4133874 Miller et al. 1/9/1979 21 22 4145410 Sears 3/20/1979 4147767 Yapel, Jr. 4/3/1979 23 Wretlind et al. 9/18/1979 24 4168308 25 4186183 Steck et al. 1/29/1980 4219548 Reller 8/26/1980 26 11/25/1980 27 4235871 Papahadjopoulos et al. Papahadjopoulos et al. 12/23/1980 28 4241046 Schmidt 6/2/1981 4271196 29 30 4298594 Sears et al. 11/3/1981 4302459 Steck et al. 11/24/1981 31 Marchetti et al. 12/29/1981 32 4308166 1/5/1982 33 4309421 Ghyczy et al. 2/23/1982 34 4316884 Alam et al. 3/16/1982 35 4320121 Sears 4/20/1982 4325871 36 Sasaki et al. 5/4/1982 4328222 37 **Schmidt** 5/11/1982 38 4329332 Couvreur et al.

		·			
Examiner Signature	Non		Date Considered	12/2/05	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

		•				7
Dinama	6 -		(+) inside this box	_		
LICOPA	INDE B	DIUS STON	(+) (NSICO (NIS DOX	_	-	•
			, ,			
		••				

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number 09/376,487-09/18/20,37/

Filing Date 8/18/99

First Named Inventor Awadhesh K. Mishra

Group Art Unit 1617

Examiner Name E. Webman

Attorney Docket Number 402090/SKYEPHARMA

| Cuse as many sheets as necessary | Sheet | Cuse as many sheets as necessary | 12

2 2 2004 **U.S. PATENT DOCUMENTS** U.S. Patent Document Examiner Application or Kind Date of Filling Date If Doc. No. Name of Patentee or Applicant **Patent Number** Code Publication -Appropriate NE 4331654 39 Morris 5/25/1982 40 4332795 Ghyczy et al. 6/1/1982 41 4332796 Los 6/1/1982 4340594 42 Mizushima et al. 7/20/1982 43 4345588 Widder et al. 8/24/1982 44 4351831 Growdon et al. 9/28/1982 4356167 Kelly 45 10/26/1982 46 4369182 Ghyczy et al. 1/18/1983 Ghyczy et al. 47 4378354 3/29/1983 4394182 48 Maddox, III 7/19/1983 4394372 **Taylor** 49 7/19/1983 4397372 DeKraker 8/9/1983 50 4397846 Weiner et al. 8/9/1983 51 Schrank et al. 10/25/1983 4411894 52 4411933 Sameiima et al. 10/25/1983 53 Ghyczy et al. 12/20/1983 54 4421747 Dingle et al. 1/24/1984 55 4427649 4448765 Ash et al. 5/15/1984 56 4452817 Glen et al. 6/5/1984 57 4474753 Haslam et al. 10/2/1984 58 Augart 1/20/1984 59 4483847 Mezei et al. 11/27/1984 4485054 60 Mosier 1/8/1985 61 4492720 5/7/1985 Deamer 62 4515736 4522803 Lenk et al. 6/11/1985 63 4529561 Hunt et al. 7/16/1985 64 4532089 MacDonald 7/30/1985 65 4588578 Fountain et al. 5/13/1986 66 Fountain et al. 9/9/1986 67. 4610868 Mizushima et al. 9/23/1986 68 4613505 4614702 Sawada et al. 9/30/1986 69 11/11/1986 Haynes 70 4622219 Ohkawara et al. 6/23/1987 71 4675236 N-E Fukushima et al. 72 8/18/1987 4687762

Examiner Signature Nature Date Considered 12/2/05

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign
patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise
explanation of relevance under 37 CFR 1.98(a)(3).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

12

101	P	A 30 85	mar	y sheets	s as ne	cessary)
Sheet		· 4	_		of	

	Complete if Known
Application Number	09/376,487 09/8 20,371
Filing Date	8/18/99
First Named Inventor	Awadhesh K. Mishra
Group Art Unit	1617
Examiner Name	E. Webman
Attorney Docket Number	402090/SKYEPHARMA

NOA	يبر 2004 ي		: U	.S. PATENT DOCUMENTS		
3 8		U.S. Patent Docume	ent			10.44.
Exampler Initials / R.	DEBUS O	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
N-C	73	4711902		Semo	12/8/1987	
	74	4719239		Muller et al.	1/12/1988	
	75	4725442		Haynes	2/16/1988	
	76	4756910		Yagi et al.	7/12/1988	
	77	4761228		Weisenbarger et al.	8/2/1988	
	78	4762720	15.	Jizomoto	8/9/1988	
	79	4766046		Abra et al.	8/23/1988	
	80	4776991		Farmer et al.	10/11/1988	4
	81	4798846	1	Glen et al.	1/17/1989	
	82	4798860		Parr	1/17/1989	
	83	4800079	7.77	Boyer	1/24/1989	
	. 84	4801455		List et al.	1/31/1989	
	85	4803070		Cantrell et al.	2/7/1989	
	86	4806350		Gerber	2/21/1989	
	87	4806352		Cantrell	2/21/1989	
	88	4826687		Nerome et al.	5/2/1989	
	89	4839111		Huang	6/13/1989	
	90	4863737		Stanley et al.	9/5/1989	
	91	4863740		Kissel et al.	9/5/1989	
	92	4895726		Curtet et al.	1/23/1990	
	93	4937078		Mezei et al.	6/26/1990	
	94	4961890		Boyer	10/9/1990	
	95	4963362		Rahman et al.	10/16/1990	
	96	4963367		Ecanow	10/16/1990	
	97	4973465		Baurain et al.	11/27/1990	
	98	5004612		Kim et al.	4/2/1991	
	99	5023087		Yau-Young	6/11/1991	
	100	5028600	1 :	Jeppsson	7/2/1991	
	101	5030453		Lenk et al.	7/9/1991	3.0
	102	5049388	1	Knight et al.	9/17/1991	
	103	5091187	1	Haynes	2/25/1992	
-+	104	5091188	1.5	Haynes	2/25/1992	
N.G	105	5098606	1	Nakajima et al.	3/24/1992	

Date Considered Examiner Signature

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet Sheets as necessary)

_		
		Complete if Known
	Application Number	09/376,487 09/826,371
	Filing Date	8/18/99
:	First Named Inventor	Awadhesh K. Mishra
	Group Art Unit	1617
	Examiner Name	E. Webman
٦	Attorney Docket Number	402090/SKYEPHARMA

N.	N 2 2 200A	3	· · · · t	J.S. PATENT DOCUMENTS		
		U.S. Patent Documer	nt			· 1, 1, 1, 1, 1
Examiner Initials	Doc Nove	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
NE	106	5100591		Leclef et al.	3/31/1992	
· .	107	5118493		Kelley et al.	6/2/1992	*
	108	5128147	·	Leveen et al.	7/7/1992	
	109	5132114		Stanley et al.	7/21/1992	
	110	5133965		Fountain	7/28/1992	
	111	5145684		Liversidge et al.	9/8/1992	
. : .	112	5147884		Diehl et al.	: 9/15/1992	
	113	5152923		Weder et al.	10/6/1992	
	114	5167950		Lins	12/1/1992	*.
	115	5179079		Hansen et al.	1/12/1993	
	116	5188837		Domb	2/23/1993	
	117	5217707		Szabo et al.	6/8/1993	
	118	5227165	٠	Domb et al.	7/13/1993	
	119	5234634	••	Janoff et al.	8/10/1993	
	- 120	5234767		Wallach	8/10/1993	
	121	5244925		Wretlind et al.	9/14/1993	
	122	5246707		Haynes	9/21/1993	· · · .
	123	5256422		Albert et al.	10/26/1993	. 44 .
	124	5256641	1. 1. 1.	Yatvin et al.	10/26/1993	
	125	5264207		Bommelaer et al.	11/23/1993	
	126	5269979		Fountain	12/14/1993	
	.127:	5288497		Stanley et al.	2/22/1994	
	128	5288498		Stanley et al.	2/22/1994	
	129	5294604		Nussenblatt et al.	3/15/1994	
	130	5298262		Na et al.	3/29/1994	
	131	5302401	٠.	Liversidge et al.	4/12/1994	
	132	5308874 ~		Sanchez et al.	5/3/1994	
	133	5314915		Rencher	5/24/1994	
	134	5326552		Na et al.	7/5/1994	
	135	5332576		Mantelle	7/26/1994	<u> </u>
	136	5336507		Na et al.	8/9/1994	<u> </u>
NIC	137	5338761		Nakajima et al.	8/16/1994	

Examiner Signature	42-		Date Considered	12/0/05	
	va		J	12/2/0_)

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign
patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise
explanation of relevance unider 37 CFR 1.98(a)(3).

	_			٠		┌
Pleasa	type a	വിശ ജ്ന	(+) insli	le this	$box \rightarrow$	
	.,,,,,	proc.ug.	(.)		· .	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Huse as many sheets as necessary)

	Complete if Known
Application Number	09/936487 820,371
Filing Date	8/18/99
First Named Inventor	Awadhesh K. Mishra
Group Art Unit	1617
Examiner Name	E. Webman
Attorney Docket Number	402000/SKYEDHADMA

NOV 2	2 2004 w		į	J.S. PATENT DOCUMENTS	<u></u>	
Examiner Initiation	2 2004 w	U.S. Patent Docum Application or	Kind	Name of Patentee or Applicant	Date of	Filing Date If
Initiation	DEM	Patent Number	Code		Publication	Appropriate
N.G		5340588		Domb	8/23/1994	
· _	139	5346702		Na et al.	9/13/1994	
	140	5352459	·	Hollister et al.	10/4/1994	
	141	5364633		Hill et al.	11/15/1994	
٠.	142	5376646		Pittrof et al.	12/27/1994	
	143	5378451		Gorman et al.	1/3/1995	·. · · · · · · · · · · · · · · · · · ·
	144	5389377		Chagnon et al.	2/14/1995	
	145	5399363		Liversidge et al.	3/21/1995	
	146	5407609		Tice et al.	4/18/1995	
	147	5409698		Anderson et al.	4/25/1995	
	148	5429824		June	7/4/1995	
	149	5446070		Mantelle	8/29/1995	
	150	5447710		Na et al.	9/5/1995	
	151	5451408	1	Mezei et al.	9/19/95	
	152	5461080		Sanchez et al.	10/24/1995	
	153	5496537	1	Henry	3/5/1996	
	154	5496811		Aviv et al.	3/5/1996	
	155	5496818	1	Schaupp et al.	3/5/1996	
	156	5498420		Mentrup Edgar et al.	3/12/1996	in district the second
- -	157	5498421		Grinstaff et al.	3/12/1996	
	158	5508275	1	Weithmann et al.	4/16/1996	
- -	159	5510118	1	Bosch et al.	. 4/23/1996	
	160	5518187		Bruno et al.	5/21/1996	
-	161	5518730	 	Fuisz	5/21/1996	
	162	5527537	 	Dieti	6/18/1996	
	163	5534270	1	De Castro	7/9/1996	
- `	164	5536413	-	Bormann et al.	7/16/1996	1.3 1.3 2.3
	165	5545628	-	Deboeck et al.	8/13/1996	
	100	0070020	+	0 1 111	0/47/4006	

Examiner Signature	Na		Date Considered	12/2/	05	·

Suddith

5556580

166

A concise statement of relevance is being submitted in fleu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in fleu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

	-				_	
	•		ide this box			
Please to	na a mhe	cion (4) inc	ida Me ho	-		٠
	o a pro-	omenia, in a second			1 1 7	
• • • • • • • • • • • • • • • • • • • •	7		•			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	LAUR	as mar	ny sheet.	s as ne	cessary)	<u>::.:</u>
Sheet		·2/6		of.		12

٠.		Complete if Known
	Application Number	09/370,487 09/820,371
	Filling Date	8/18/99
	First Named Inventor	Awadhesh K. Mishra
	Group Art Unit	1617
•	Examiner Name	E. Webman
_	Attorney Docket Number	402090/SKYEPHARMA

NOV 2 2 2004			· · · · · · · · · · · · · · · · · · ·	J.S. PATENT DOCUMENTS				
• •	Doc Mos	U.S. Patent Docume Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate		
NE	167	5560931		Eickhoff et al.	10/1/1996			
	168	5569464	· · · · ·	Endo et al.	10/29/1996			
	169	5571536		Eickhoff et al.	11/5/1996			
	170	5576012		Bauer et al.	11/19/1996			
	171	5576016	. :	Amselem et al.	11/19/1996			
	172	5589455	•	Woo	12/31/1996			
	173	5589598		Paiocchi	12/31/1996			
	174	5591311		Ramachandran	1/7/1997			
	175	5603951		Woo	2/18/1997			
	176	5607694	. :	Marx	3/4/1997			
	177	5618522		Kaleta et al.	4/8/1997			
	178	5618563		Berde et al.	4/8/1997			
	179	5626869		Nyqvist et al.	5/6/1997			
	180	5631019		Marx	5/20/1997			
	181	5635203		Gale et al.	6/3/1997			
	182	5635205		Nyqvist et al.	6/3/1997			
	183	5635536		Lyons	6/3/1997	<i>y</i> %		
	184	5635540		Edlich et al.	6/3/1997			
	185	5639474		Woo	6/17/1997	100		
NE	186	5641508		Li et al.	6/24/1997			
					· · · · · · · · · · · · · · · · · · ·			
			•					
·								
	· · · · · .							

Examiner Signature Date Considered 12/2/05

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

		•			
Please	hma	a plus sign	(4) incida	this hay	-
	·ypo	a been astri	1.10000		

		Complete if Known
Substitute for form 1449A/B/PTO	Application Number	09/376,487 09/820,871
INFORMATION DISCLOSURE	Filing Date	8/18/99
	First Named Inventor :	Awadhesh K. Mishra
STATEMENT BY APPLICANT	Group Art Unit	1617
OIP (Bisbas many sheets as necessary)	Examiner Name	E. Webman
Sheet 6 7 of 12	Attorney Docket Number	402090/SKYEPHARMA

0 1101	2 2004 _U	U.S. PATENT DOCUMENTS							
Examiner, Initials	ODUSTIO.	U.S. Patent Docume Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate			
N:C	187	5645856	5005	Lacy et al.	7/8/1997	у фрифици			
	188	5648375		Abraham	7/15/1997				
	189	5651982		Marx	7/29/1997				
	190	5651991		Sugiyama et al.	7/29/1997	\			
.	191	5656280		Herb et al.	8/12/1997				
	192	5656286		Miranda et al.	8/12/1997				
	193	5656289		Cho et al.	8/12/1997				
	194	5658583		Zhang et al.	8/19/1997				
	195	5660837		Lundquist	8/26/1997				
	196	5660854		Haynes et al.	8/26/1997				
	197	5660858		Parikh et al.	8/26/1997	ti se etc			
	198	5662932		Amselem et al.	9/2/1997				
	199	5665380		Wallach et al.	9/9/1997				
• .	200	5665700		Cho et al.	9/9/1997				
	201	5667809		Trevino et al.	9/16/1997				
	202	5677341	٠	Lyons	10/14/1997				
	203	5686102		Gross et al.	11/11/1997				
	204	5693337		Suzuki et al.	12/2/1997				
	205	5700482	1.5	Frederiksen et al.	12/23/1997				
	206	5705039		Clarke et al.	1/6/1998				
	207	5719197		Kanios et al.	2/17/1998				
	208	5731355		Jones et al.	3/24/1998				
	209	5731356		Jones et al.	3/24/1998				
	210	5733572	<u> </u>	Unger et al.	3/31/1998				
	211	5747060		Sackler et al.	5/5/1998	11.			
	212	5750137 -		Taskovich et al.	5/12/1998				
	213	5750142	T	Friedman et al.	5/12/1998				
	214	5753258	1	Schreier et al.	5/19/1998				
	215	5756120		Hersch et al.	5/26/1998				
	216	5756121		Bracken	5/26/1998				
	217	5759571	1	Hersch et al.	6/2/1998				
	218	5766625		Schreier et al.	6/16/1998				
	219	5766627	<u> </u>	Sankaram et al.	6/16/1998				
. 	220	5770222	1	Unger et al.	6/23/1998				
Ne		5773026		Schlipalius	6/30/1998				

Date Considered Examiner Signature

A concise statement of relevance is being submitted in ileu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

					•	_
				nside this	_	
Diane	-		-1 /-\1	anida ibia		
T IGGGGG	(ADS: 5	1 124425	3WI (7) (IISIUB IIIS		_
	75					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

.12

Sheet 8 of

_		
		Complete if Known
	Application Number	09/378,487 09/820, 27
	Filing Date	8/18/99
	First Named Inventor	Awadhesh K. Mishra
	Group Art Unit	1617
	Examiner Name /	E. Webman
	Attorney Docket Number	402090/SKYEPHARMA

WY 2 7 2004		<u> </u>				
	U.S. Patent Document Application or Kir Patent Number Co		ent			
Examiner Initials	Doct to.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
N-€	222	5773106		deGroot et al.	6/30/1998	
1	223	5776488		Mori et al.	7/7/1998	A Profit
344	224	5776495	٠.	Duclos et al.	7/7/1998	
	225	5780045		McQuinn et al.	7/14/1998	
	226	5785976	· .	Westesen et al.	7/28/1998	
	227	5785989		Stanley et al.	7/28/1998	
:	228	5785991		Burkoth et al.	7/28/1998	
	229	5789411		Gooberman et al.	8/4/1998	
	230	5807316		Teeple, Jr.	9/15/1998	
	231	5807534		Pomato et al.	9/15/1998	
	232	5807572		Kim et al.	9/15/1998	
	233	5807573		Ljusberg-Wahren et al.	9/15/1998	
	234	5827533		Needham	10/27/1998	
	235	5827534		Fasano	10/27/1998	
	236	5827822		Floc'h et al.	10/27/1998	
	237	5843465		Lundquist	12/1/1998	
.	238	5843468		Burkoth et al.	12/1/1998	
	239	5843474		Williams	12/1/1998	
	240	5853755		Foldvari	12/29/1998	
	241	5855908		Stanley et al.	1/5/1999	
	242	5858398		Cho	1/12/1999	
	243	5858401		Bhalani et al.	1/12/1999	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	244	5858410		Muller et al.	1/12/1999	
	245	5882676		Lee et al.	3/16/1999	
	246	5885172		Hebert et al.	3/23/1999	
	247	5885597		Botknecht et al.	3/23/1999	
	248	5908619		Scholz	6/1/1999	
	249	5908825	•	Fasano et al.	6/1/1999	
	250	5908869	· .	Jones et al.	6/1/1999	
	251	5912007		Pan et al.	6/15/1999	
	252	5912271		Brodin et al.	6/15/1999	
	253	5916596	: •	Desai et al.	6/29/1999	
V-6	254	5922340	· .	Berde et al.	7/13/1999	
	·. ·					
			· .			

Examiner Signature	Na	Date Considered	12/2	105	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign
patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise
explanation of relevance under 37 CFR 1.98(a)(3).

	• •					- 1	_	
Please type a				. •.			٠.	1.
Diagram and a	ahaa ada		L) lacide	s (bio		-	_	
ribasa iyya a	hine out	י) נע	r) assuc	Juus	- CO		_	
. ••			•					

		Complete if Known
Substitute for form 1449A/B/PTO	Application Number	-09/376,487> 0
INFORMATION DISCLOSURE	Filing Date	8/18/99
	First Named Inventor	Awadhesh K. Mishra
STATEMENT BY APPLICANT	Group Art Unit .	1617
(Use as many sheets as necessary)	Examiner Name	E. Webman

12

of

NM 2	2 2004			J.S. PATENT DOCUMENTS	<u> </u>	
Esaminer Initials	Dog No.	U.S. Patent Docume Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If
Nie	255	5922355		Parikh et al.	7/13/1999	
	256	5922705		Simon	7/13/1999	
	257	5925014		Teeple Jr.	7/20/1999	
	258	5932243		Fricker et al.	8/3/1999	
	259	5942497		Fukunaga et al.	8/24/1999	
	260	5945510	7.	Fasano	8/31/1999	
	261	5958379		Regenold et al.	9/28/1999	
	262	5958449		Hersch et al.	9/28/1999	
	263	5962536		Komer	10/5/1999	
	264	5972366		Haynes et al.	10/26/1999	
	265	5972938		Rupniak et al.	10/26/1999	
- 4	266	5980936		Krafft et al.	11/9/1999	
	267	5990176		Bieniarz et al.	11/23/1999	
	268	5993850		Sankaram et al.	11/30/1999	
	269	5994318		Gould-Fogerite et al.	11/30/1999	
	270	6004566		Friedman et al.	12/21/1999	
	271	6004962		Gooberman	12/21/1999	- 1
	272	6011067		Hersh	1/4/2000	
	273	6013665		DeMichele et al.	1/11/2000	
	274	6017513		Betbeder et al.	1/25/2000	
	275	6019997		Scholz et al.	2/1/2000	
	276	6022547		Herb et al.	2/8/2000	
	277	6024976	·.	Miranda et al.	2/15/2000	
	278	6025362		Fukunaga et al.	2/15/2000	
V. E	279	6028066		Unger	2/22/2000	
: :			٠,			
	:: ·.		, , ; ,			
· .	٠.					

Attorney Docket Number

Mishra

402090/SKYEPHARMA

No

Examiner Signature

Date Considered

A concise statement of relevance is being submitted in fleu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in fleu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

•	_	•			
Please type a					1 1.
Please type a	a paus sign (+) 🛭	isioo uii	3 DOX	1
••		٠.		:	1 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

OIP	es as many sheet	s as nec	essary)	
heet	% 10	of		12

_		
		Complete if Known
٠.	Application Number: -	-09/376,487- 09/8 20,37/
;	Filling Date	8/18/99
•	First Named Inventor	Awadhesh K. Mishra
	Group Art Unit	1617
	Examiner Name	E. Webman
	Attorney Docket Number	402090/SKYEPHARMA

		Z ZUUA	•				
		ببو	1	_	I.S. PATENT DOCUMENTS		
Exami Initia	ner Is	ndias Na	U.S. Patent Docume Application or Patent Number	ent Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
N	6	280	6031007		Brodin et al.	2/29/2000	3
- 1		281	6046163		Stuchlik et al.	4/4/2000	
		282	6046187		Berde et al.	4/4/2000	
٠, .		283	6054421	÷	Lyons et al.	4/25/2000	
		284	6057289		Mulye	5/2/2000	
	•	285	6063762		Hong et al.	5/16/2000	. <u>.</u> 11. : 12
		286	6071534		Kim et al.	6/6/2000	
		287	6071927		Baker et al.	6/6/2000	
:	•	288	6071928		Curtis et al.	6/6/2000	
		289	6071933		Joo et al.	6/6/2000	
		290	6071974		Patel et al.	6/6/2000	
		291	6075059		Reader	6/13/2000	
		292	6079416		Williams	6/27/2000	, ,
		293	6086376	٠. ,	Moussa et al.	7/11/2000	•
		294	6086911		Godbey	7/11/2000	
•		295	6096338		Lacy et al.	8/1/2000	
		296	6103269		Wunderlich et al.	8/15/2000	
		297	6106848		Preuilh et al.	8/22/2000	
		298	6106858		Ye et al.	8/22/2000	
		299	6113921		Friedman et al.	9/5/2000	
		300	6117066	٠	Abrams et al.	9/12/2000	
	·	301	6120797		Meers et al.	9/19/2000	
		302	6121261		Glatt et al.	9/19/2000	
		303	6123923		Unger et al.	9/26/2000	
]	304	6132766		Sankaram et al.	10/17/2000	
1		305	6153217		Jin et al.	11/28/2000	
Ni	6	306	6160007		DeMichele et al.	12/12/2000	
	•						
A	\cdot			· .			<u> </u>

Examiner Signature	N= -	Date C	Considered	212/05	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise. explanation of relevance under 37 CFR 1.98(a)(3).

•			•		• .	1		٠.
Please	type 8	olus	sign (+)	inside t	his box	→	Н	-
	.,,,			_				1 3

INFORMATION DISCLOSURE

101	dUse as many she	ets as nec	essary)	<u>.</u>
Sheet	× ×1	. of		12.

-		
		Complete if Known
	Application Number	109/375,487 09/820,371
	Filing Date	8/18/99
	First Named inventor	Awadhesh K. Mishra
•	Group Art Unit	1617
	Examiner Name	E. Webman
٦	Attorney Docket Number	402090/SKYEPHARMA

Souther	. NOV 2 2 2004		I.S. PATENT DOCUMENTS				
Patent Number Code Code Publication Appropriate	•		U.S. Patent Docume	ent .			
№ 307 6180136 Larson et al. 1/30/2001 308 6190894 Thomfeldt et al. 2/20/2001 309 6197323 Georgieff 3/6/2001 310 6204257 Stella et al. 3/20/2001 311 6217886 Önyüksel et al. 4/17/2001 312 6221383 Miranda et al. 4/24/2001 313 6228399 Parikh et al. 5/6/2001 314 6232311 Rupniak et al. 5/15/2001 315 6224446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6284917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 628127	Examiner Initials	Doc Na O	Application or Patent Number		Name of Patentee or Applicant		
309 6197323 Georgieff 3/6/2001 310 6204257 Stella et al. 3/20/2001 311 6217886 Onyüksel et al. 4/17/2001 312 6221383 Miranda et al. 4/24/2001 313 6228399 Parikh et al. 5/8/2001 314 6232311 Rupniak et al. 5/8/2001 315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/17/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6289127 Bienlarz et al. 9/11/2001 326 6294191 Meers et al. 9/11/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 11/6/2001 329 6309623 Weers et al. 11/6/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6323708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 12/18/2001 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002	NG		6180136			1/30/2001	1. 31 · 3
310 6204257 Stella et al. 3/20/2001 311 6217886 Onyūksel et al. 4/17/2001 312 6221383 Miranda et al. 4/24/2001 313 6228399 Parikh et al. 5/8/2001 314 6232311 Rupniak et al. 5/18/2001 315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/17/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/3/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/14/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bienlarz et al. 9/11/2001 326 6294191 Meers et al. 9/11/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 9/25/2001 321 6274633 Franks et al. 19/11/2001 322 628175 Control et al. 19/11/2001 323 6281240 Regan et al. 19/11/2001 324 628000 Müller et al. 19/11/2001 325 6284127 Bienlarz et al. 19/11/2001 326 6294191 Meers et al. 19/25/2001 327 6294192 Patel et al. 19/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 12/18/2001 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/71/2002 338 6391336 Royer 5/21/2002		308	6190894	٠.	Thornfeldt et al.	2/20/2001	
311 6217886 OnyOksel et al. 4/17/2001 312 6221383 Miranda et al. 4/24/2001 313 6228399 Parikh et al. 5/8/2001 314 6232311 Rupniak et al. 5/15/2001 315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6286040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 11/6/2001 329 6309623 Weers et al. 11/6/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 12/18/2001 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391832 Lyons et al. 5/21/2002		309	6197323	* : * :	Georgieff	3/6/2001	
312 6221383 Miranda et al. 4/24/2001 313 6228399 Parikh et al. 5/8/2001 314 6232311 Rupniak et al. 6/5/2001 315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Moller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 11/6/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgleff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6391336 Royer 5/21/2002 338 6391336 Royer 5/21/2002		310	6204257		Stella et al.	3/20/2001	
313 6228399 Parikh et al. 5/8/2001 314 6232311 Rupniak et al. 5/15/2001 315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/13/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/14/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/14/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/11/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6363471 Chen et al. 12/18/2001		311	6217886	1	Önyüksel et al.	4/17/2001	
314 6232311 Rupniak et al. 5/15/2001 315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/12/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/14/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Muller et al. 9/11/2001 325 628127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/11/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6332138 Hull et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6362234 Hendler 3/26/2002 336 639234 Chen et al. 5/7/2002 337 639832 Lyons et al. 5/7/2002		312	6221383	7 .	Miranda et al.	4/24/2001	
315 6242446 Glatt et al. 6/5/2001 316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Muller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/11/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgleff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 639234 Hendler 3/26/2002 337 6383471 Chen et al. 57/2002 338 6391336 Royer 5/21/2002		313	6228399	: :	Parikh et al.	5/8/2001	
316 6254853 Hendler et al. 7/3/2001 317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Huil et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6391336 Royer 5/21/2002		314	6232311		Rupniak et al.	5/15/2001	
317 6261537 Klaveness et al. 7/17/2001 318 6264917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6261242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6352138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 12/18/2001 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 57/2002 338 6391336 Royer 5/21/2002		315	6242446		Glatt et al.	6/5/2001	•
318 6264917 Klaveness et al. 7/24/2001 319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 9/11/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/11/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTormaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002		316	6254853		Hendler et al.	7/3/2001	
319 6264981 Zhang et al. 7/24/2001 320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 9/11/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hender 3/26/2002 337 6383471 Chen et al. 577/2002 339 6391832 Lyons et al. 5/21/2002	1.1	317	6261537		Klaveness et al.	7/17/2001	
320 6267985 Chen et al. 7/31/2001 321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6352138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 339 6391832 Lyons et al. 5/21/2002		318	6264917		Klaveness et al.	7/24/2001	
321 6274633 Franks et al. 8/14/2001 322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		319	6264981		Zhang et al.	7/24/2001	
322 6281175 Lyons et al. 8/28/2001 323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 337 6383471 Chen et al. 5/71/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		320	6267985		Chen et al.	7/31/2001	
323 6281242 Regan et al. 8/28/2001 324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		321	6274633		Franks et al.	8/14/2001	
324 6288040 Müller et al. 9/11/2001 325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002	7 -	322	6281175	• •	Lyons et ai.		
325 6288127 Bieniarz et al. 9/11/2001 326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		323	6281242		Regan et al.	8/28/2001	
326 6294191 Meers et al. 9/25/2001 327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/71/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		324	6288040		Müller et al.		
327 6294192 Patel et al. 9/25/2001 328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		325	6288127		Bieniarz et al.	9/11/2001	
328 6297985 Kang 10/2/2001 329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		326	6294191		Meers et al.		
329 6309623 Weers et al. 10/30/2001 330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		327	6294192		Patel et al.	9/25/2001	
330 6312715 Cantor et al. 11/6/2001 331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/71/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		328	6297985			10/2/2001	
331 6326406 DeTommaso 12/4/2001 332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/71/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		329	6309623		Weers et al.	10/30/2001	
332 6328708 Georgieff 12/11/2001 333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Urnezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		330	6312715		Cantor et al.		
333 6331289 Klaveness et al. 12/18/2001 334 6332138 Hull et al. 12/18/2001 335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		331	6326406	:	DeTommaso	12/4/2001	
334. 6332138 Hull et al. 12/18/2001 335. 6350480 Urnezis et al. 2/26/2002 336. 6362234 Hendler 3/26/2002 337. 6383471 Chen et al. 5/7/2002 338. 6391336 Royer 5/21/2002 339. 6391832 Lyons et al. 5/21/2002		332	6328708		Georgieff .		
335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		333	6331289 ~	,	Klaveness et al.	12/18/2001	
335 6350480 Umezis et al. 2/26/2002 336 6362234 Hendler 3/26/2002 337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002		334	6332138		Hull et al.		
337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002			6350480	•	Umezis et al.	2/26/2002	
337 6383471 Chen et al. 5/7/2002 338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002	1. 1.	336	6362234		Hendler		
338 6391336 Royer 5/21/2002 339 6391832 Lyons et al. 5/21/2002					Chen et al.	5/7/2002	
339 6391832 Lyons et al. 5/21/2002			6391336		Royer		
	7			·	Lyons et al.	5/21/2002	
N < 340 6399087	Nie				Zhang et al.	6/4/2002	

Examiner Signature	Na	Date Considered 12/2/05

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

	lus sign (+) Inside th	
M	h al (a) lackla th	
Plaasa Ivoe a d	1113 SKUN (*) U SAUG U I	
		. 111

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

IP	₹Vse as	s many	sheets	as ned	essary)
2 1		40 ÷		-4	

		Complete if Known
	Application Number	99 1070,487 09 120,371
	Filing Date	8/18/99
	First Named Inventor	Awadhesh K. Mishra
	Group Art Unit	1617
	Examiner Name	E. Webman
•	Attorney Docket Number	402090/SKYEPHARMA

· NOV 2	يبر 2 2004			J.S. PATENT DOCUMENTS		<u> </u>
Examiner Initials	$ec{\mathcal{E}}$	U.S. Patent Docume Application or Patent Number	ent Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
20	341	6410583		Labelle et al.	6/25/2002	
	342	6423338		Larson et al.	7/23/2002	•
	343	2001/0007663		Von Corswant	7/12/2001	
	344	2001/0046474		Weers et al.	11/29/2001	
	345	2002/0006442A1		Mishra et al.	1/17/2002	
	346	Re. 32393		Wrettind et al.	4/7/1987	
NE	347	Re. 35338		Haynes	9/24/1996	
,						
						A Charles Const.
: 1 <u>4</u>						
: .						
						, ,
			·			
					137 1457 1 1 1 1	
			-			
			 			
			 			

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number (s), publisher, city and/or country where published.		No*+
	348	Letter regarding Collection/Validity Search of Amphiphilic Lipid-Coated Drug Formulations dated November 3, 2000		
	349	Letter regarding Collection/Validity Search of Surface-Stabilized Particles dated November 6, 2000.		
•				

Examiner Signature	No.15 Date	te Considered 12/5/05	
· · · · · · · · · · · · · · · · · · ·			

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

. INFO	KM	ATION DISCLOSURE		OCKET NO.	SERIAI		20	1/20	6
		CHAIIOID	9 121-1		- 09/3	76,487	_ 09	1820) _/ -
		9 200	- , All GO	INT	. •				
		(KON 1 a con	` EMISH	IRA et al					
. (Use	several sheets (Specessary)	FILING D	ATE	GROUP	•			
		soveral shoot specessary)	Augu	st 18, 1999	. 1617	7	•		•
	<u> </u>		<u> </u>	S. PATENT DOCUMENTS	•				
XAMINER		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING	
INITIAL.	<u> </u>	5,589,508	12/96	Schlotzer et al		COASS	BUBLIASS	IF APPRO	PRIA
	\vdash	0,000,000	12.00	00,110,201,01,01			 		
	Н		-					· ·	 ·
	Н					:	- : : -		<u> </u>
	\vdash								<u></u>
	Н					· · · ·			
	ш		FO	REIGN PATENT DOCUMEN	TS		<u> </u>		- : :
		<u> </u>		NEIGHT ATENT DOCUMENT				TRANSL	ATIO
•		DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	YES	NC
NE		0 770 387 A1	5/97	Europe		-		F .	
٠,									•
	\Box	:				,			,
· . ·					_		1 (1	1.5	
				,					• .
	:								
	$\overline{}$								
					•				
		OTHER DOC	UMENTS (I	ncluding Author, Title, Date	, Pertinent	pages,	etc.)	٠.	
	\dashv		· · · · · · · · · · · · · · · · · · ·						<u></u>
	_		· · · · ·		: :	·	• •	····	<u> </u>
	. 1		·	Date Consid		2/8/	٥5		
 aminer	-	Notion			IOPON ! !	0181			

	CITATION	121-1 APPUC		09/3	76,487	091	1820,
) (1	ise several sheets if necessary)	•	IRA et al	GROU	Þ		
·.		Augu	st 18, 1999	161′			
· :			J.S. PATENT DOCUMENTS			·	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
N.G	5,714,520	2/98	Jones et al.		1	1	1 ATROPAGE
NE	4,056,635	11/77	Glen et al.		 	<u> </u>	<u> </u>
NE	5,637,625	6/97	Haynes		 		
					<u> </u>	 	
					 		
					 		
					 	 	
				<u> </u>	· · · · ·	 	
					 		
				•		ļ	ļ
				- :		· · · ·	
· · ·							
				<u> </u>			
· · · · ·				· .			
		· · · · · ·	· · · · · · · · · · · · · · · · · · ·				
						٠.	
					·		
		· · · · ·					
· : ·					:		
		FO	REIGN PATENT DOCUMENTS	•			
	• • • •			•		:	TRANSLATION
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	YES NO
T	DOCUMENT	DATE	COUNTRY	· · · · · ·	CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	
				artinont			
N.E	OTHER DOCU	JMENTS (i	ncluding Author, Title, Date, Pent fat emulsion* Pharmaceutic		pages, o	etc.)	YES NO
N.E	OTHER DOCU	JMENTS (i	ncluding Author, Title, Date, P		pages, o	etc.)	YES NO
N.E	OTHER DOCU	JMENTS (i	ncluding Author, Title, Date, P		pages, o	etc.)	YES NO
N.E	OTHER DOCU	JMENTS (i	ncluding Author, Title, Date, P		pages, o	etc.)	YES NO
N,E	OTHER DOCU	JMENTS (i	ncluding Author, Title, Date, P	al Resea	pages, o	etc.)	YES NO

INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF A A G,100,302 8/00 Pejaver et al. 514 731 Ap Barrier Subclass IF A A FOREIGN PATENT DOCUMENTS	LING DATE
(Uso several absorbs if noccisiony) MISHRA et al FILING DATE August 18, 1999 1617 U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER AND ATE NAME CLASS SUBCLASS IF A 731 Ap Pejaver et al. 514 731 Ap FOREIGN PATENT DOCUMENTS	LING DATE
FILING DATE GROUP August 18, 1999 1617 U.S. PATENT DOCUMENTS TEXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF A NAME SUBCLASS OF A SUB	PPROPRIATE
FILING DATE GROUP August 18, 1999 1617 U.S. PATENT DOCUMENTS TEXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF A NAME SUBCLASS OF A SUB	PPROPRIATE
U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FA	PPROPRIATE
U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FA	PPROPRIATE
EXAMINER NITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF A FAIT A G., 100,302 8/00 Pejaver et al. 514 731 Ap	PPROPRIATE
INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF A 6,100,302 8/00 Pejaver et al. 514 731 Ap Pejaver et al. 514 731 Ap Pejaver et al. 514 731 Ap FOREIGN PATENT DOCUMENTS	PPROPRIATE
FOREIGN PATENT DOCUMENTS	
FOREIGN PATENT DOCUMENTS	ril 5, 1999
FOREIGN PATENT DOCUMENTS	٠,
FOREIGN PATENT DOCUMENTS	•
FOREIGN PATENT DOCUMENTS	
FOREIGN PATENT DOCUMENTS	•
FOREIGN PATENT DOCUMENTS	
FOREIGN PATENT DOCUMENTS TR	
FOREIGN PATENT DOCUMENTS TR	
FOREIGN PATENT DOCUMENTS TR	-
FOREIGN PATENT DOCUMENTS TR	
FOREIGN PATENT DOCUMENTS TR	
TR	
TR	
DOCUMENT DATE COUNTRY CLASS SUBCLASS YE	ANSLATION .
	s no
	٠.
	Ĭ : ·
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)	
	··
Examiner Na Date Considered 12/5/05	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not conside copy of this form with next communication to application.	

	CITATION	121-	175	- 09/ 3	76,487	09/8	320	1371
		APPLI	CANT	•	4. **	· .		
_)		MIS	HRA et al	• •			٠.	
. (1	Jse several sheets if necessary)	FILING	DATE	GROU	P			
		Aug	ust 18, 1999	1617	7	:		
			U.S. PATENT DOCUMENTS					
*EXAMINER							FILING	DATE
NITIAL N.C.	DOCUMENT NUMBER 5,478,860	12/1995	NAME Wheeler et al	<u> </u>	CLASS	SUBCLASS	IF APPR	OPRIATE
10,10	5,688,528	11/1997	Carlsson et al	-		<u> </u>	 	
	6,028,108	2/2000					ļ	
		10/2000	George			ļ	 	· ··
	6,140,373		May et al			 	-	<u> </u>
	6,140,374	10/2000	May et al				· ·	
	6,147,122	11/2000	Mirejovsky et al					
	6,150,423	11/2000	Carpenter	<u> </u>	·			
N.E	6,177,477	1/2001	George et al					
·							<u> </u>	<u>.</u>
	· · · · · · · · · · · · · · · · · · ·			··	· .			
				· ·	<u> </u>			
							, .	<u> </u>
								•
		<u> </u>			1			
		<u> </u>						
						2.2		
.:								
; u					· .		. "	
		FC	REIGN PATENT DOCUMENTS		· · ·			
.*	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	TRANSI	LATION NO
NE	WO 00/59471	10/2000	WIPO			1		
10 10	WO 00/59471	10/2000	WIPO					
	WO 00/39472 WO 00/78301	12/2000	WIPO					
			WIPO					
	W/O 97/10814	1 3/100/						
<u> </u>	WO 97/10814	3/1997						<u> </u>
ν,ς	WO 97/10814 WO 98/53805	3/1997	WIPOW					
ν,ς	· · · · · · · · · · · · · · · · · · ·							
ν, ζ	· · · · · · · · · · · · · · · · · · ·							
N, C	WO 98/53805	3/1998	WIPOW					
Ν , ε	WO 98/53805	3/1998		ertinent	pages,			
ν. ε	WO 98/53805	3/1998	WIPOW	ertinent	pages,			
<i>λ</i> , ε	WO 98/53805	3/1998	WIPOW	ertinent	pages,			
ν. ε	WO 98/53805	3/1998	WIPOW Including Author, Title, Date, P	ertinent	pages,			
ν. ε	WO 98/53805	3/1998	WIPOW	ertinent	pages,			
ν. ε	WO 98/53805	3/1998	WIPOW Including Author, Title, Date, P	ertinent	pages,			
ν, ε	WO 98/53805	3/1998	WIPOW Including Author, Title, Date, P	ertinent	pages,			
ν. ε	WO 98/53805	3/1998	WIPOW Including Author, Title, Date, P	ertinent	pages,			

ATTY, DOCKET NO.

SERIAL NO.

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE

Please type	e plus sign	(+) inside this b	ox 🗝

		Complete if Known
Substitute for form 1448A/B/PTO	Application Number	9/376:487 OH/820/37/
INFORMATION DISCLOSURE	Filing Date	August 18, 1999
	First Named Inventor	MISHRA
STATEMENT BY APPLICANT	Group Art Unit	1617
(Use as many sheets as necessary)	Examiner Name	E. Webman
Sheet 1 of 2	Attorney Docket Number	402000

			U	.S. PATENT DOCUMENTS		٠
		U.S. Patent Docu				
Examiner: Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
N 6	1	4,056,635		Glen et al.	11/1/1977	
	2	4,280,996		Okamoto et al.	7/28/1981	
	3	4,309,421	,,	Ghyczy et al.	1/5/1982	
	4	4,340,594		Mizushima et al.	7/20/1982	
,	. 5	4,687,762		Fukushima et al.	8/18/1987	
	- 6	4,837,028		Allen	6/6/1989	:
	7	4,880,634		Speiser	11/14/1989	
	. 8:	4,895,726		Curtet et al.	1/23/1990	
	9	5,023,087		Yau-Young	6/11/1991	
	10	5,100,591		Ledef et al.	3/31/1992	
	11	5,320,906		Eley et al.	6/14/1994	
	12	5,527,537		Dietl	6/18/1996	
	. 13	5,827,520	· .	de Salvert	10/27/1998	
	14	5,827,536		Laruelle	10/27/1998	
	- 15	5,880,148		Edgar et al.	3/9/1999	
N .C	16					

		<u> </u>			N PATENT DOCUMENTS	. "1.		
• • •		F	oreign Patent Document				Trans	lation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No
NE	17	DE	25 13 797		ICI Ltd.	10/9/975		X+
	18	DE	29 38 807	· .	Green Cross Corp.	11/13/1980		X+
	19	DE	3421 468		Rentschler Arzenimittel	12/19/1985		X+
	20	EP	052 322	÷	Gersonde Klaus Prof Dr	5/26/1982		Χ÷
	21 .	EP	057 829		Fullard	8/18/1982		
	22	EP	272 091		Vestar, Inc.	6/22/1988		
	2.3	EP	330 532		Fournier Innovation Synergie	8/30/1989		X+
	24	EP	391 369		Yissum Research Dev.	10/10/1990		•
	25	EP	418 153	٠.	Medgenix Group SA	3/20/1991		X+
	26	EP	456 670		Braun Melsungen AG	11/21/1991		X+
	27	EP	456 764	•	Braun Melsungen	11/21/1991		X
	28	EP	499 299		Sterling Winthrop Inc.	8/19/1992		
	29	EP	535 567		Braun Melsungen AG	4/7/1993	: :	X+
	30	EP	570 829		Hans	11/24/1993		X+
	-31	EP	601 618	,	Sterling Winthrop Inc.	6/15/1994		
	32	EP	602 700		Sterling Winthrop Inc.	6/22/1994		
	33	EP	724 877		Fournier Lab SA	8/7/1996		X٠
1	34	EP	757 911		CLL Pharma	2/12/1997	,	X٠
	35	EP	770 387		B. Braun Melsungen AG	5/2/1997		
N · a		EP.	770 381		Oreal	5/2/1997		Χ¹

		·	 	
-	Examiner Signature	Noz	 Date Considered	12/5/05

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

				ı
		a plus sign (+) inside this box>		
Manage		a also oles (A) isoleta this have	-	
PIESSE	IYDE			
	••			

					
	Complete if Known				
Substitute for form 1449A/B/PTO	Application Number	9/376,487 09/82037/			
INFORMATION DISCLOSURE	Filing Date	August 18, 1999			
, ·	First Named Inventor	MISHRA			
STATEMENT BY APPLICANT	Group Art Unit	1617			
(Use as many sheets as necessary)	Examiner Name	E. Webman			
Sheet 2 of 2	Attorney Docket Number	402090			

· · ·	· .				N PATENT DOCUMENTS		•	
	Foreign Patent Document Application or Kind				Trans	Translation		
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
N.C.	. 37	EP	814 787		AstraZeneca AB	1/7/1998	·	
· .	38	EP	1 238 677		AstraZeneca AB	9/11/2002		
	39 .	FR	2 265 357		ICI Ltd.	10/24/1975		- X+
	. 40	FR	2 617 047		Sanofi SA/Fournier Labs.	12/30/1988		X+
	. 41	JP	55-141407		Nattermann A & CIE	11/5/1980		X+
1	42	JP	56-167616	٠, ٠	Green Cross Corp.	12/23/1981		X+
	43	JP	60-208910		Green Cross Corp.	10/21/85		X+
	44	J <u>P</u>	63-502117			8/18/1988		X+
	45	JP	63-233915		Besutaa Res. Inc.	9/29/1988		X+
1	46	JP ·	1-502590		Liposome Tech. Inc.	9/7/1989		X+
	47	HU	211 580		Egis Gyogyszergyar Rt.	12/28/1995		X+
1	48	PCT	WO 85/00011		The University of Miami	1/3/1985		
1	49	PCT	WO 87/04592		Liposome Tech. Inc.	8/13/1987		· ·
	50	PCT	WO 91/04011		Riker Labs., Inc.	4/4/1991		
	51	PCT	WO 93/19736		Kabi Pharmacia AB	10/14/1993		·
i	52	PCT	WO 94/20072		Pharmacia AB	9/15/1994		
	53	PCT	WO 96/01637	77. 1	Astra Aktiebolag	1/25/1996		
	54	PCT	WO 96/19064		Xcellenet, Inc.	6/20/1996		
	55	PCT	WO 96/21439		Galephar P.R. Inc.	7/18/1996	•	
	56	PCT	WO 96/29064		Zeneca Ltd.	9/26/1996		
	57	PCT	WO 97/10814		Vesifact AG	3/27/1997		
1	58	PCT	WO 97/14407		Research Triangle Pharmaceuticals	4/24/1997		
1	59	PCT	WO 98/53805		Saucy Ltd.	12/3/1998		•
	60	PCT	WO 99/39696		Gensia Sicor Inc.	8/12/1999		
•	61	PCT	WO 00/10531		RTP Pharma Inc.	3/2/2000		,
1.	62	PCT	WO 00/24376		Abbott Labs.	5/4/2000		
	63	PCT	WO 00/54588		Krusz	9/21/00		
	64	PCT	WO 00/59471		Baxter International, Inc.	10/12/2000		
	65	PCT	WO 00/59472	1	Baxter International, Inc.	10/12/2000		
	66	PCT	WO 00/78301		Kuhnil Pharm. Co. Ltd.	12/28/2000		
11	67	PCT	WO 01/30372		BASF Aktiengesellschaft	5/3/2001		X+
	68	PCT	WO 02/21517	1	Zeon Corp.	3/14/2002		X+
	69	UK	2 046 094	A. Nattermann & Cie 11/12/1980				
1	7.0	UK	2 250 197	1	Egis Gyogyszergyar	6/3/1992		·
NIC	71	UK	2 298 789	1	Zeneca Ltd.	9/18/1996		<u> </u>

•					
	Examiner Signature	Not	Date Considered	12/5/05	

A concise statement of relevance is being submitted in fleu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary Sheet

Complete if Known							
Application Number	09/970/107 09/800,37/						
Filing Date	August 18, 1999						
First Named Inventor	MISHRA						
Group Art Unit	1617						
Examiner Name .	E. Webman						
Attorney Docket Number	402090/SKYEPHARMA						

<u></u>		<u> </u>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Tran	slation
lr	aminer iitials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-tissue number (s), publisher, city and/or country where published.	Yes	No
N	U = 1 "Diprivan 1% Injection," Physicians' Desk Reference, 1996, pp. 2833-39.		*Diprivan 1% Injection,* Physicians' Desk Reference, 1996, pp. 2833-39.		
		2	"Diprivan 1% Injection," Physicians' Desk Reference, 1999, pp. 3411-18.		
•		3	Ardulno, M.J. et al., "Microbial Growth and Endotoxin Production in the Intravenous Anesthetic Propofol", Infection Control and Hospital Epidemiology, Vol. 12, No. 9, September 1991, pp. 535-539.		
		4	Babl et al., "New Formulations of Propofol in an LCT/MCT Emulsion: Approach to Reduce Pain on Injection", Eur. Hosp. Pharmacy, January 1995, Vol. 1, No. 1, pp. 15-21.		
		5	Bangham et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J. Mol. Biol., 1965, 13:238-251.		
		6	Bennett et al., "Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol", Vol. 333, No. 3, July 20, 1995, pp. 147-154.		
		7	Benz et al., "Electrical Capacity of Black Lipid Films and of Lipid Bilayers made from Monolayers," Biochimica et Biophysica Acta, 1975, 394:323-334.		
		8	Bergmann, Ludwig, Der Ultraschall, 5 Aufl., 1949, Struttgart, pp. 551-564 and 665-677.		X
		9	Bittman, Robert, "Sterol-Polyene Antibiotic Complexation: Probe of Membrane Structure," LIPIDS, Vol. 13, No. 10, pp. 686-691 (1978).		:
		10	Cairns et al., "Tolerance of Mixed Lipid Emulsion in Neonates: Effect of Concentration", Archives of Disease in Childhood, 1996, Vol. 75, p. F113-F116.		
		11	Cherney, Leonid S., "Tetracaine Hydrolodide: A Long-Lasting Local Anesthetic Agent for the Relief of Postoperative Pain," Anesthesia and Analgesia, Vol. 42, No. 4, July-Aug. 1963, pp. 477-481.		
		12	Crowther et al., "Growth of Microorganisms in Propofol, Thiopental and a 1:1 Mixture of Propofol and Thiopental", Anesth. and Anal., (1996), 82, pp. 475-478.	:	
		13	Cudd et al., "Liposomes Injected Intravenously into Mice Associate with Liver Mitochondria," Biochimica et Biophysica Acta, (1984), 774:169-180.		
		14	De Sommer et al., "A Comparative Study on the Effects of Propofol in Emulsion and Intralipid [®] on Fat Metabolism," Acta Anesthesiologica Belgica, Vol. 41, No. 2, 1990, pp. 133-138.		•
· ·		15	Dewandre et al., "A Comparison of the 2% and 1% Formulations of Propofol During Anaesthesia for Craniotomy," Anesthesia, 1994, Vol. 49, pp. 8-12.		
		16	Doenicke, A.W. et al., "Pharmacokinetics and Pharmacodynamics of Propofol in a New Solvent", Anesth. Analg., (1997), 85:1399-403.		
/\	1,6	17	Doenicke, A.W. et al., "Reducing Pain During Propofol Injection: The Role of the Solvent", Anesth. Analg., (1996), 82:472-4.		5

Examiner	A1-	Date 12/5/05
Signature	Ne	Considered 121310

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

^{An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).}

		• •		•			
Please	type	a ptus sign	(+)	inside this	\rightarrow	-	Н
	.,,						

				Complete if Known
Substitute for form 1449A/B/PTO			Application Number	-09/376,487- OP/820, 371
INFORMATIO	N DISCLO	SIIPE	Filing Date	August 18, 1999
	•		First Named Inventor	MISHRA
STATEMENT BY APPLICANT			Group Art Unit	1617
(Use as many s	reets as necessary	0	Examiner Name	E. Webman
Sheet 2	of	3	Attorney Docket Number	402090/SKYEPHARMA

Examiner		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Tran	station
Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	· No*
NE	18	Eddleston et al., "The Effect on Serum Lipid Concentrations of a Prolonged Infusion of Propofol – Hypertriglyceridaemia Associated with Propofol Administration," Intensive Care Med., (1991), 17:424-426.		
	19	Ewart et al., "Forum: 2% Propofol for Sedation in the Intensive Care Unit, A Feasibility Study", Anaesthesia, February 1992, Vol. 47, No. 2, pp. 146-148.		
	20	Freeman, Andrew B., "A Technique for Reducing Pain Associated with Propofol Administration," Anesth. Analg., 1992, 74:311-319,		
	21	Ghouri et al., *Effect of Flumazenil on Recovery after Midazolam and Propofol Sedation*, Anesthesiology, (1994), 81:333-339.	· :	
	22	Goodman & Gillman's The Pharmacological Basis of Therapeutics, 7 th Ed., MacMillan Publishing Co., New York, 1985. p.312.		
	23	Gottardis et al., Effect of Prolonged Sedation with Propofol on Serum Triglyceride and Cholesterol Concentrations, British J. Anaesthesia, (1989) 62:393-396.		
	24	Gregoriadis, Gregory, "The Carrier Potential of Liposomes in Biology and Medicine", The New England Journal of Medicine, September 23, 1976, Vol. 295, pp. 704-710.		
1.0	25	Haung et al., "Interaction of the N-terminus of Sterol Carrier Protein 2 with Membranes: Role of Membrane Curvature," Biochem. J., (1999), 344:593-603.	:	
	26	Haynes et al. "Ultra-Long Duration Local Anesthesia Produced by Intra-Dermal Injection of Lecithin-Coated Methoxyflurane Microdroplets", Proceed. Intern. Symp. Control. Rel. Bloact. Mater., (1987), 14:293-294 (Extended abstract)		
	27	Haynes et al., "Ultra-long-duration Local Anesthesia Produced by Injection of Lecthin-coated Methoxyfluorene Microdroplets", Anesthesiology, November 1985, Vol. 63, No. 5, pp. 490-499.		
	28	Haynes, Duncan H., "Divalent Cation-Ligand Interactions of Phospholipid Membranes: Equilibria and Kinetics," Metal-Ligand Interactions in Organic Chemistry and Biochemistry, Pullman and Goldblum, Eds., part 2, @1977, pp. 189-212		
	29	King et al., "Lidocaine for the Prevention of Pain Due to Injection of Propofol," Anesth. Analg., 1992, 74:246-249.		:
	30	Kirkpatrick et al., "Local Anesthetic Efficacy of Methoxyflurane Microdroplets in Man," Anesthesiology, 1987, 67(3A):A254, Abstract only.		
	31	Lindholm, Marianne, "Critically III Patients and Fat Emulsions," Minerva Anesthesiology, 1992, Vol. 58, No. 10, pp. 875-879.		
	32	Mangar et al., "Tourniquet at 50 mm Hg Followed by Intravenous Lidocaine Diminishes Hand Pain Associated with Propofol Injection", Anesth. Analg., (1992), 74:250-252.		
	33	Mirakhur et al., "Induction Characteristics of Propofol in Children: Comparison with Thiopenttone", Anesthesia, (1998), 43:593-598.		
	34	Mishra et al., "Scientifically Speaking: Novel Injectable Formulations of Water-insoluble Drugs", Controlled Release Newsletter, Vol. 17, Issue 2, June 2000, pp.21-30		
11.4	35	Nichols, Ronald Lee, "Bacterial Contamination of an Anesthetic Agent," New Engl. J. Med., (1995), 333(3), 184-185.		

Examiner Signature	Date Considered 12/5/05

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

	Please type a plus sign (+) inside this box ->	7	_
--	--	---	---

				1.0	Complete if Known
Substitute for for	m 1449A/B/PTO	1449A/B/PTO		Application Number:	09/376,487 09/820,371
INFO	RMATION	DISC	CLOSURE	Filing Date	August 18, 1999
INFORMATION DISCLOSURE				First Named Inventor	MISHRA
SIAI	STATEMENT BY APPLICANT			Group Art Unit	1617
	(Use as many sheet	s as ne	cessary)	Examiner Name	E. Webman
Sheet	3	of	3	Attorney Docket Number	402090/SKYEPHARMA

·		OTHER - NON PATENT LITERATURE DOCUMENTS		•			
Examiner Initials Doc. No.		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes No*				
NE	36	Rompp, "Emulsion", Chemie-Lexikon, 2 Aufl., Bd. 1, 1950, Stichwort.		. :,			
	37	Ross, et al., "Aqueous Solutions of Surface-Active Solutes", Colloidal Systems and Interfaces, @ 1988, p. 148-151		X			
	3.8	Sande et al., "Antimicrobial Agents: Antifungal and Antiviral Agents," p. 1219-1222.					
	39	Sandstrom et al., "Structured Triglycerides Were Well Tolerated and Induced Increased Whole Body Fat Oxidation Compared With Long-Chain Triglycerides in Postoperative Patients," Journal of Parenteral and Enteral Nutrition, (1995), 19(5):381-6.					
	40	Sklar, Grant E., *Propofol and Postoperative Infections,* The Annals of Pharmacotherapy, (1997), 31:1521-3.					
	41	Smith et al., "Propofol: An Update on its Clinical Use," Anesthesiology, Oct. 1994, Vol. 81, No. 4, pp. 1005-1043.					
	42	Sosis et al., "Growth of Staphylococcus aureus in Four Intravenous Anesthetics," Anesth. Anal., (1993), Vol. 77, pp. 766-768					
	43	Sosis et al., "Propofol, but not Thiopental, Supports the Growth of Candida albicans," Anesth. Anal., (1995), Vol. 81, pp. 132-134.					
	44	Stark, et al., "A review of the safety and tolerance of propofol ('Diprivan')", Postgraduate Medical Journal, 1985, Vol. 61, Suppl. 3, pp. 152-156.		-			
	45	Stenz et al., "A new physiologically approached in vitro test for quick evaluation of the hemolytic activity of surfactants," Pharmazie, (1996), 51(5), pp. 283-287.					
	46	Tessler et al., "Growth curves of Staphyloccoccus aureus, Candida albicans, and Moraxella osloensis in propofol and other media", Can. J. Anaesth., 1992, 39 (5), pp. 509-511.					
	47	White et al., "Sedative Infusions During Local and Regional Anesthesia: A Comparison of Midazolam and Propofol", J. Clin. Anesth., Jan/Feb 1991, Vol. 3, pp. 32-39.					
NE	48	Wu et al., "Pharmacokinetics of Methoxyflurane after its Intra-dermal Injection as Lecithin-Coated Microparticles", Journal of Controlled Release, 1989, Vol. 9, pp. 1-12.					

Examiner Signature	N.	•	Date Considered	12/5/0	5

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

		Complete if Known				
Substitute for form 1449A/B/PTO	Application Number	09/878,487 09/820,571				
INFORMATION DISCLOSUR	C!!! O	August 18, 1999				
	I First Named Inventor	MISHRA				
STATEMENT BY APPLICAN	Group Art Unit	1617				
(Use as many sheets as necessary)	Examiner Name	E. Webman				
Sheet 1 of 2	Attorney Docket Number	402090/SKYEPHARMA				

		U.S. Patent Docum		J.S. PATENT DOCUMENTS		
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date I Appropriate
NG	1	6,028,108		George	2/22/2000	
	2	6,140,374		May et al.	10/31/2000	
	3	6,140,373		May et al.	10/31/2000	
· [.]	4	6,147,122		Mirejovsky et al.	11/14/2000	
	5	6,177,477		George et al.	1/23/2001	
	6	6,197,323	·	Georgieff	3/6/2001	
	7	2001/0008889		Caruso et al.	7/19/2001	
	8	6,284,267		Aneja	9/4/2001	
	9	6,291,013		Gibson et al.	9/18/2001	
	10	2001/0025035		Stella et al.	9/27/2001	
	. 11	2001/0041923		Dobak, III	11/15/2001	
	12	6,322,810		Alkan-Onyuksel et al.	11/27/2001	
	13	2001/0051595	1 1 1	Lyons et al.	12/13/2001	
	14	2002/0002704	·	Davis et al.	1/3/2002	
	15	2002/0003179	, ,	Verhoff et al.	1/10/2002	
	16	2002/0016373		Bieniarz et al.	2/7/2002	
	17	2002/0017296		Hickle	2/14/2002	
	18	2002/0017299		Hickle	2/14/2002	
7:1	19	2002/0017300	•	Hickle et al.	2/14/2002	
	20	2002/0022667		Pace et al.	2/21/2002	· . · · · · · · · · · · ·
	21	2002/0025337		Illum et al.	2/28/2002	
	22	2002/0032171		Chen et al.	3/14/2002	
	23	2002/0035141		Attala	3/21/2002	
	24	2002/0035161		Segura et al.	3/21/2002	
	25	2002/0037933		Basu et al.	3/28/2002	
	26	6,365,190		Gordon et al.	4/2/2002	
1.1	27	6,368,619		New et al.	4/9/2002	
	28	2002/0047058		Verhoff et al.	4/25/2002	
	29	2002/0058009		Bartus et al.	5/16/2002	
	30	2002/0068764		Franks et al.	6/6/2002	
	3.1	2002/0071852		Deckers et al.	6/13/2002	
-1-1	32	2002/0082252		Hochman	6/27/2002	
7-1	33	6,413,527		Simonnet et al.	7/2/2002	
.	34	6,419,949		Gasco	7/16/2002	
	35	2002/0102217		Klaveness et al.	8/1/2002	· · · · · · · · · · · · · · · · · · ·
	36	2002/0102216		Lanza et al.	8/1/2002	
N/B	- 37	2002/0102215		Klaveness et al.	8/1/2002	
- 1					1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

Date Considered **Examiner Signature**

A concise statement of relevance is being submitted in tieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box ->	F	7

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	COOD BOTTOMY GROOM	3 63 1100	
Sheet	2	of	. 2

Complete if Known					
Application Number	09/376,487 09/820.37/				
Filing Date	August 18, 1999				
First Named Inventor	MISHRA				
Group Art Unit	1617				
Examiner Name	E. Webman				
Attomey Docket Number	402090/SKYEPHARMA				

		U.S. Patent Docu	ment			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If
NE	38	2002/0102281		Auberger et al.	8/1/2002	
	39	2002/0107291		De Tommaso	8/8/2002	1, 1
	40	2002/0107265		Chen et al.	8/8/2002	1
	41	6,433,040		Deliamary et al.	8/13/2002	
	42	6,436,367		Modi	8/20/2002	
	43	6,436,430		Mulye	8/20/2002	
	44	2002/0115609		Onyuksel et al.	8/22/2002	
	4 5	6,440,456		Nguyen et al.	8/27/2002	
;	46	6,440,493		Gibson et al.	8/27/2002	
	47	2002/0120015		Dennis et al.	8/29/2002	
·	48	2002/0120002		Baker et al.	8/29/2002	
	49	6,444,859		Bieniarz et al.	9/3/2002	
	50	2002/0128698		Dobak, ill et al.	9/12/2002	
	5.1	6,451,339		Patel et al.	9/17/2002	
	52	2002/0142093		Gibson et al.	10/3/2002	
	53	6,464,987		Fanara et al.	10/15/2002	
	54	2002/0150621		Kohane et al.	10/17/2002	
	55	6,469,069		Mirejovsky et al.	10/22/2002	
	56	2002/0160043		Coleman	10/31/2002	
	57	6,475,506	•	inoue et al.	11/5/2002	
NE	58	2002/0173547		Jones et al.	11/21/2002	·.

	•				FOREIG	N PATENT DOCUMENTS	•	٠ ,	- ". '
Examiner Initials			Foreign Patent Document					Translation	
		Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
2	16	59	JP	10-251142		Michael	9/22/1998	٠.	X+
		60	JP	2000-119177		Torii Yakuhin KK	4/25/2000		X+
٠.		61	JP	2002-179562	٠.	Towa Yakuhin KK	6/26/2002		X+
	1	62	PCT	WO 96/32135		Farmarc Nederland BV	10/17/1996	· ·	
	T	63.	PCT	WO 02/074200		Cydex, Inc.	9/26/2002		
5	Ď	64	UK.	2 359 747		Maelor Pharmaceuticals Ltd.	9/5/2001		
		• .•		, ,	J				:
·		•							
					1				

Examiner Signature	Na	Da	te Considered	12/5/05	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-tanguage equivalent/patent, or an English-tanguage abstract, or an English-tanguage version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

INFORM	ATION DISCLOSURE	ATTY. DOCK	SERIAL	NO.							
	CITATION	121-272	to be as	ssigned							
		APPLICANT	·								
		MISHRA et	al								
(Usa d	everal sheets if necessary)	FILING DATE		GROUP			Ť				
		March 23, 2	001	Error!	Refere	nce s	ource	not fou	ind.		
 		U.S. F	ATENT DOCUMENTS						-		
AMINER	DOCUMENT NUMBER	DATE		SUBCLASS		FILING IF APPR	DATE OPRIAT				
IIIIAL T	4,056,635	11/1977	NAME Gien et al		CLASS						
-, -	5,478,860	12/1995	Wheeler et al		٨		Γ				
- - -	5,589,508	12.1996	Schlotzer et al								
	5,637,625	6/1997	Haynes								
	5,688,528	11/1997	Carlsson et al								
 	5,714,520	2/1998	Jones et al								
	6,028,108	2/2000	George								
- -	6,100,302	8/2000	Pejaver et al								
	6,140,373	10/2000	May et al								
- - -	6,140,374	10/2000	May et al								
	6,147,122	11/2000	Mirejovsky et al								
-1-1-	6,150,423	11/2000	Carpenter								
N-	6,177,477	1/2001	George et al								
- 					7						
-V 						_		<u> </u>			
		FOREI	GN PATENT DOCUMENTS	3							
	DOCUMENT	DATE	COUNTRY		CLASS	SUB	CLASS	YES	LATION NO		
/*) WO 00/59471		10/2000	WIPO			_					
//	WO 00/59471 WO 00/59472	10/2000	WIPO		4.		i				
/ - -	WO 00/38472 WO 00/78301	12/2000	WIPO								
	WO 97/10814	3/1997	WIPO		1	1 1			1		
	WO 98/53805	3/1998	WIPO		\neg	17					
-	0 770 387 A1	5/1997	Europe								
	077030771	37.007									
<i>#</i>											
	OTHER DOC	UMENTS (Incl)	ding Author, Title, Date,	Pertinent	pages.	etc.)					
	Cox et al "Influence of	different fat em	ulsion" Pharmaceutical Re	search V	ol. 15, N	o. 3,	3/1998	3, pp 44	2-448		
	OVA BE BE TERMINOTION OF	GIII OIL IGE OIL									
											

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

*Examiner

Date Considered

Form PTO-FB-A820 (Also PTO-1449)

6/04